GE HealthCare (GEHC) Q4 2024 Earnings Transcript

GE HealthCare reported Q4 revenue of $5.3 billion, with organic growth of 2%, adjusted EBIT margin expansion of 260 basis points to 18.7%, and adjusted EPS up 23% to $1.45. Orders rose 6% organically, backlog hit a record $19.8 billion, and management guided 2025 revenue growth of 2%-3% with adjusted EPS of $4.61-$4.75 and free cash flow of at least $1.75 billion. The outlook includes a 1.5% FX headwind and about 10 bps of tariff impact, partly offset by strength in PDx, AVS, enterprise deals, and upcoming Flyrcado launch.

Analysis

GEHC’s setup is increasingly a backlog-conversion story rather than a top-line growth story. The key second-order signal is that enterprise wins and NPIs are now functioning as a moat: they lock in multi-year demand, raise switching costs, and shift mix toward higher-margin recurring revenue and consumables. That matters because the market is likely still underestimating how quickly the model can re-rate once order conversion normalizes in 2H25 and the launch cadence compounds into 2026.

The main near-term overhang is not demand, but timing: China remains a revenue drag in 1H25, FX shaves reported growth, and tariff commentary gives management cover for conservative guidance. That conservatism may actually be bullish if the company beats on margins again, because the current setup bakes in enough caution that any better-than-feared China stabilization or faster Flyrcado uptake becomes a clean multiple catalyst. The risk is that backlog grows faster than revenue for too long, which would expose the cash conversion gap and keep investors focused on execution slippage rather than strategic progress.

Contrary to the headline, this is not a pure capital equipment recovery; the real upside is in mix. Imaging and AVS are becoming delivery vehicles for software, AI, and procedure-enabling platforms, while PDx is emerging as the highest-quality earnings engine with a runway for capacity-led growth. Competitively, the firm is gaining share less by stealing sockets outright and more by monetizing its own installed base at higher ASPs, which should pressure peers that rely on one-time equipment cycles without a comparable recurring layer.

Key Decisions for Investors

• Long GEHC into the next 3-6 months: guidance is conservative versus order momentum, so the asymmetric trade is a beat-and-raise path if 2H25 China recovery and backlog conversion arrive on schedule.
• Buy GEHC Jan-2026 calls / call spreads to express upside from Flyrcado, AI-enabled product penetration, and enterprise deal monetization; the catalyst window is 2H25 through 2026 launch cycle.
• Pair long GEHC / short a more equipment-cycle-sensitive med-tech peer basket over 1-2 quarters to isolate the recurring revenue and margin expansion story from broader hospital CapEx noise.
• Use any post-print weakness near support to add: the downside is capped by backlog and margin structure, while upside re-rates on any evidence of faster sales conversion or China stabilization.
• Hedge with a tactical short in China-exposed med-tech names if tariff or provincial procurement headlines worsen; GEHC’s relative exposure is already partially guided out, making it a better defensive long than direct China bet.